iSpecimen (NASDAQ:ISPC) Releases Earnings Results
by Tristan Rich · The Markets DailyiSpecimen (NASDAQ:ISPC – Get Free Report) released its earnings results on Wednesday. The company reported ($0.74) earnings per share (EPS) for the quarter, FiscalAI reports. iSpecimen had a negative return on equity of 531.78% and a negative net margin of 343.86%.The company had revenue of $0.05 million for the quarter.
iSpecimen Trading Down 3.2%
NASDAQ ISPC opened at $0.15 on Thursday. The firm’s 50 day simple moving average is $0.27 and its 200 day simple moving average is $0.54. The firm has a market capitalization of $1.49 million, a price-to-earnings ratio of -0.02 and a beta of 1.98. iSpecimen has a 1 year low of $0.14 and a 1 year high of $3.18.
Institutional Investors Weigh In On iSpecimen
A hedge fund recently bought a new stake in iSpecimen stock. Scientech Research LLC purchased a new stake in iSpecimen Inc. (NASDAQ:ISPC – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned about 0.30% of iSpecimen as of its most recent filing with the Securities and Exchange Commission. 13.62% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of iSpecimen in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.
Read Our Latest Report on ISPC
About iSpecimen
iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.
Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.